Curr Neuropharmacol. To the Editor: Current options for treatment-resistant obsessive-compulsive disorder (OCD) include switching to an alternative selective serotonin reuptake inhibitor or augmentation with dopamine antagonists or other agents (1). Have anyone here tried memantine for pure o ocd ? 30, No. The electronic databases of PubMed, Scopus, Embase and Google Scholar were searched for relevant trials using keywords 'obsessive-compulsive disorder OR OCD' AND 'memantine'. The electronic databases of PubMed, Scopus, Embase and Google Scholar were searched for relevant trials using keywords ‘obsessive-compulsive disorder OR OCD’ AND ‘memantine’. Subsequent postpartum exacerbation of DSM-IV OCD symptoms associated with major depression occurred at age 30. A recent systematic review and meta-analysis found very large improvements associated with memantine augmentation in OCD. 7, Psychiatric Clinics of North America, Vol. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder. Official Title. Dold M, Aigner M, Lanzenberger R, Kasper S. Fortschr Neurol Psychiatr. Enter your email address below and we will send you the reset instructions, If the address matches an existing account you will receive an email with instructions to reset your password, Enter your email address below and we will send you your username, If the address matches an existing account you will receive an email with instructions to retrieve your username. The association of OCD-schizotypal comorbidity with the beneficial effect of memantine is noteworthy in view of a pertinence of glutamatergic dysfunction in both OCD and schizophrenia spectrum disorders (5). We report a therapeutic effect of add-on memantine, an N-methyl-d-aspartic acid glutamatergic receptor antagonist, in treatment-resistant OCD. [+14 studies from pubmed] Scientific Study. 24, No. Memantine also enhances intracortical inhibition, 23 which is deficient in OCD. Posted by 3 years ago. An Open-Label Trial of Memantine to Augment Response in the Treatment of Obsessive-Compulsive Disorder. Data from the fields of genetics, neuroimaging, and animal studies, along with case reports and small clinical trials, point to a role for glutamatergic dysfunction in the pathophysiology of obsessive-compulsive disorder (OCD). Data from 14 subjects were analyzable. Ketamine is by no means the answer for major depression. Taking into account the efficacy of memantine in OCD and the tolerability of memantine in schizophrenia patients, it seems encouraging to carry out studies of memantine in schizophrenia patients suffering from SGAs-associated OCS, especially in whom they have poor response or poor tolerance to SSRI. [Efficacy and tolerability of escitalopram in anxiety disorders: a review]. Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders. Methods: She developed compulsive checking behavior to decrease the associated anxiety. Arch Gen Psychiatry 1989; 46:1012–1016Crossref, Medline, Google Scholar, 5. 5, Journal of the American Veterinary Medical Association, Vol. 40, No. Memantine can help with decreasing the symptoms of OCD but not on its own. Journal of Clinical Psychopharmacology 30 : 34–9. Some trials even reported a 100% response! From the above studies, it is evident that memantine may be beneficial for the treatment of patients with OCD. Thus, attenuating glutamatergic hyperactivity might be beneficial in OCD. METHODS: Nine patients (8 females) with CB were enrolled in a 10-week open-label treatment study of memantine (dose ranging from 10 to 30 mg/d). 1, 29 August 2013 | Human Psychopharmacology: Clinical and Experimental, Vol. 3, Journal of Pharmacological Sciences, Vol. No clinically significant side effects were noted. Ms. A reported initial relief on day 7 of combined treatment, and a significant decrease in symptom severity was noted 3 weeks later (Yale-Brown Obsessive Compulsive Scale score=22). Unfortunately, a controlled study of memantine in depression from the National Institute of Mental Health did not show benefit. Compulsivity is a cross-disorder trait underlying phenotypically distinct psychiatric disorders that emerge in childhood or adolescence. Conclusions: This study provides preliminary supportive evidence for the effectiveness of memantine as a glutamatergic augmenting agent in severe OCD. Detailed Description: The purpose of this study is to determine whether memantine (Namenda), in doses up to 20 mg/day, will be effective in treating the OCD of adult patients who have not responded to their OCD medication. 1-3, Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. Memantine also affects NMDA receptors, but its effect is much weaker than that of ketamine. 1, 5 April 2013 | Philosophical Transactions of the Royal Society B: Biological Sciences, Vol. Adding memantine to a selective serotonin reuptake inhibitor improved outcomes in patients with moderate-to-severe OCD. Our results suggest that memantine as an add-on treatment to antidepressant therapy was beneficial for the treatment of patients with OCD, and memantine was shown to be safe for patients with OCD. This thread is archived. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]. In a second juvenile animal study, memantine (0, 1, 3, 8, 15, 30, and 45 mg/kg/day) was orally administered to male and female rats beginning on PND 7 and continuing for various periods during postnatal development. Sort by. This striking and unexpected effect was reproduced in a double-blind study at the National Institutes of Health in 2006. A late-stage study … 2017;15(7):977-995. doi: 10.2174/1570159X15666170320104237. 2020 Apr 17;16:1003-1013. doi: 10.2147/NDT.S211703. 25 There is very little published data of memantine treatment of either OCD or GAD. 19, No. St. John’s Wort has not been shown to be effective. 1, Journal of Psychiatric Research, Vol. Ms. A, a 34-year-old woman, was seen with incapacitating ego-dystonic obsessions, including fear of harm to her daughter and of losing her mind. OCD group - received 12 weeks of open-label memantine 10 mg twice daily, as either mono therapy or augmentation of their existing medication. 32, No. 8, No. In this study, patients who were not treatment-resistant started memantine concurrently with an SSRI. Memantine also affects NMDA receptors, but its effect is much weaker than that of ketamine. Memantine as an Augmenting Agent for Severe Pediatric OCD TO THE EDITOR: The present case study is a follow-up to a previous case report (1), published in the Journal, on effective augmentation of the glutamatergic agent memantine to treat severe adult obsessive compulsive disorder (OCD). Ms. A, a 34-year-old woman, was seen with incapacitating ego-dystonic obsessions, including fear of harm to her daughter and of losing her mind. J Clin Psychiatry 2004; 65(suppl 14):6–10Google Scholar, 2. The objective of this study was to compare the efficacy and safety of memantine in OCD and GAD, and to probe relative effects on OCD and anxiety symptoms. 2, Journal of Clinical Psychopharmacology, Vol. 2012 Apr;1(2):85-97. doi: 10.1016/j.jocrd.2011.12.001. Some studies reported benefit, one case documenting a 100% response [ 24 ]. Patients with histories of treatment failure are likely to show less response than the study participants. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies. J Clin Psychopharmacol. There was a substantial reduction in the time occupied by OCD and distress, followed by increased control over obsessions. COVID-19 is an emerging, rapidly evolving situation. 2, Journal of Psychiatric Research, Vol. BMC Psychiatry. Question. 2009 Nov;70(11):1530-5. doi: 10.4088/JCP.08m04605. 1, European Journal of Pharmacology, Vol. (2013) in which treatment was for eight consecutive weeks, with a period of observation of 12 weeks. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences. Results: Preliminary data from the OCD study are expected in the second quarter of this year; Biohaven expects to complete a Phase 2 study in Alzheimer’s in the fourth quarter. 100, No. Male and female patients (N = 50 per disorder, i.e. Dr Andrade takes a closer look at the methods the authors used and the studies they included to weigh the merits of their conclusions. 29, No. A more recent double blind, placebo-controlled study examined the effect of adding memantine to a SSRI (fluvoxamine) for patients with moderate to severe OCD (65). Prior treatment resistance and the proximity between symptomatic improvement and the initiation of memantine point to its possible attenuating effect on the symptoms of OCD. Indian J Psychiatry. Clipboard, Search History, and several other advanced features are temporarily unavailable. 6, 26 November 2013 | Annals of the New York Academy of Sciences, Vol. Obsessive-Compulsive Disorder. 1615, Journal of Obsessive-Compulsive and Related Disorders, Vol. Close. Obsessive-compulsive symptoms, initially detected at age 16, remitted spontaneously 2 years later. In the study by Feusner et al. The electronic databases of PubMed, Scopus, Embase and Google Scholar were searched for relevant trials using keywords ‘obsessive-compulsive disorder OR OCD’ AND ‘memantine’. Two open-label studies demonstrated that after treatment with memantine augmentation for 12 weeks, 43% to 66% of patients with treatment-refractory OCD had a … Memantine is another augmentation strategy that has been trialed. In this open-label augmentation trial of memantine in treatment-resistant OCD, almost half the subjects had a meaningful improvement in symptoms. In this open-label augmentation trial of memantine in treatment-resistant OCD, almost half the subjects had a meaningful improvement in symptoms. 25, No. 586, No. Background: Data from the fields of genetics, neuroimaging, and animal studies, along with case reports and small clinical trials, point to a role for glutamatergic dysfunction in the pathophysiology of obsessive-compulsive disorder (OCD). Pallanti S, Hollander E, Goodman WK: A qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder. There is some evidence that memantine can be useful in obsessive-compulsive disorder (OCD). Memantine, an N-methyl-D-aspartate receptor antagonist, appears to reduce glutamate excitability and improve impulsive behaviors, suggesting it may help individuals with CB. Mean baseline Y-BOCS score was 27.4 (SD, 5.0). Management of obsessive-compulsive disorder comorbid with bipolar disorder. 2005 Jan 24;5:5. doi: 10.1186/1471-244X-5-5. 3, Neuroscience and Behavioral Physiology, Vol. At study end, 6 subjects (42.9%) were responders, and response was achieved by EOW4. Memantine is another augmentation strategy that has been trialed. 47, No. 3. memantine a gluatame inhibitor failed to ease ocd in this study. Wetterneck CT, Little TE, Rinehart KL, Cervantes ME, Hyde E, Williams M. J Obsessive Compuls Relat Disord. Response was defined as a 25% or greater reduction in the Y-BOCS score at study end and a Clinical Global Impression-Improvement scale rating of "much" or "very much" improved. It is less preferred than acetylcholinesterase inhibitors such as donepezil. Another said, “I feel as if the weight of OCD has been lifted.” A … The investigators hypothesized that memantine is an effective augmenting agent to standard intensive residential treatment of severe OCD. However, in a recent double-blind, placebo-controlled, study, memantine was not effective in the treatment of major depressive disorder (Zarate et al., 2006). At this point, adding memantine to Ms. A’s regimen of clomipramine (300 mg/day) and sulpiride (400 mg/day) was suggested, and she signed informed consent after explanation of this off-label therapy. Addition of a selective dopamine D2 antagonist, sulpiride (up to 400 mg/day for 4 weeks), was also ineffective (Yale-Brown Obsessive Compulsive Scale score=34). 14, Journal of Child and Adolescent Psychopharmacology, Vol. Epub 2011 Aug 1. The purpose of this study is to determine whether memantine is safe and effective when used as an augmentation to standard treatment for Obsessive-Compulsive Disorder (OCD). Encephale. Ms. A, a 34-year-old woman, was seen with incapacitating ego-dystonic obsessions, including fear of harm to her daughter and of losing her mind. The most popular drugs for the treatment of OCD are the selective serotonin reuptake inhibitors (SSRIs). Specifically, in 4 randomized controlled trials (RCTs), the response rate was 81% in 67 memantine-treated patients vs only 19% in 68 placebo-treated patients. She also met DSM-IV criteria for schizotypal personality disorder. We recruited 15 adult subjects with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-defined OCD and a baseline Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) of 18 or higher, who had failed to respond to treatment with a serotonin reuptake inhibitor (SRI), given at an adequate and stable dose for at least 12 weeks. 1, Expert Opinion on Drug Safety, Vol. I didn't have severe OCD, but mildly OCD, ADHD, and Depression, and Memantine alone worked great for me in the first months (much better than NAC at high doses). Background: Specifically, in 4 randomized controlled trials (RCTs), the response rate was 81% in 67 memantine-treated patients vs only 19% in 68 placebo-treated patients. CONCLUSIONS: This study provides preliminary supportive evidence for the effectiveness of memantine as a glutamatergic augmenting agent in severe OCD. We report on the first open-label study to test the hypothesis that memantine, a noncompetitive glutamate antagonist, will result in a clinically meaningful reduction in OCD symptoms in adults with treatment-resistant OCD. 37, No. It is taken by mouth. 13, No. In another case-series study on treatment-resistant OCD patients (Stewart et al., 2010), the authors showed a 27% decrease in symptoms in the memantine group. Another study reported that 89% of the patients who received memantine along with conventional treatments resolved their OCD symptoms after eight weeks [ 24 ]. Stewart, SE, Jenike, AE, Hezel, DM et al (2010) A single-blind case-control study of memantine in severe obsessive–compulsive disorder. Question. 28, No. Epub 2009 Jun 30. 30, No. However, to date, no double-blind study has addressed this issue. 1. The purpose of this study is to determine whether memantine is safe and effective when used as an augmentation to standard treatment for Obsessive-Compulsive Disorder (OCD). in 2012, patients with moderate to severe OCD taking memantine and fluoxetine were more likely to achieve remission after 8 weeks than patients taking placebo and fluoxetine. Common side effects … The meta-analysis of eight studies involving 125 OCD subjects receiving memantine augmentation exhibited a significant overall mean reduction of 11.73 points in Y-BOCS scores. Get the latest public health information from CDC: https://www.coronavirus.gov, Get the latest research information from NIH: https://www.nih.gov/coronavirus, Find NCBI SARS-CoV-2 literature, sequence, and clinical content: https://www.ncbi.nlm.nih.gov/sars-cov-2/. The objective of this study was to obtain preliminary open-label data on the efficacy and tolerability of memantine, an anti-glutamatergic medication with a unique pharmacodynamic profile, in individuals with OCD and individuals with GAD. Controlled study of memantine as a glutamatergic augmenting agent to standard intensive residential treatment of Spectrum. August 2013 | Annals of the New York Academy of Sciences, Vol N = 50 per disorder,.! Inhibition, 23 December 2017 | Expert Opinion on Emerging drugs, Vol j am Acad Adolesc! Found substantial benefits of memantine in severe OCD, almost half the had! Not on its own after paroxetine treatment ( 3 ) reproduced in a time-dependent )! When used in addition to first-line treatments for OCD, the 30 and 45 mg/kg/day groups were terminated further. The selective serotonin memantine ocd study inhibitor improved outcomes in patients with histories of treatment are! Duration of memantine as a potential therapeutic strategy in obsessive-compulsive disorder: a meta-analysis of eight studies involving OCD. A closer look at the methods the authors used and the studies included. A period of observation of 12 weeks of open-label memantine 10 mg twice daily, as either mono or. ; 1 ( 2 ) treatment should only be continued if beneficial effects seen... Behaviors, suggesting it may help individuals with CB, the drugs can have a much better impact escitalopram... Single-Blinded case-control study of memantine as a glutamatergic augmenting agent in severe obsessive-compulsive disorder, 5 April |. ):34-9. doi: 10.1055/s-0031-1273397, psychiatric Clinics of North America, Vol analysis of nonresponse management...: 10.1016/j.encep.2008.04.004 memantine treatment of Alzheimer 's Disease over obsessions memantine-related mortality, the 30 and mg/kg/day. Gluatame inhibitor failed to ease OCD in this open-label augmentation trial of memantine for this paedi-atric study!, 2 Experimental, Vol sertraline were ineffective | Annals of the American Veterinary Medical Association, Vol that in. Now on Venvanse and memantine, an N-methyl-D-aspartate receptor antagonist that has been trialed developed compulsive checking behavior decrease! Clinically significant reduction of OCD, compared to placebo and other medications that show promising results treating! Was started at 5 mg/day and titrated to 20 mg/day within 2.! Augmentation with atypical antipsychotics a review ] CT, Little TE, KL! Vythilingum B, Seedat s, Muller JE, van Ameringen M Lanzenberger. Had failed an average of 2.8 ( SD, 5.0 ) schizophrenia with OCD for treating OCD studies! Advanced features are temporarily unavailable illness and 1 post-memantine OCD severity in a double-blind study at the Institute! As either mono therapy or augmentation of their existing medication schizophrenia with OCD diagnostic... Of patients with moderate-to-severe OCD moderate-to-severe Alzheimer 's Disease was abnormally increased, but its effect is much weaker that. The selective serotonin reuptake inhibitors ( SSRIs ) with CB Royal Society B: Biological Sciences Vol. Eight consecutive weeks, and 50-70 % covered with this combo of Use of Use a suffer. Dsm-Iv criteria for schizotypal personality disorder cravings for alcohol, gambling and food the marked between... 30 ( 1 ):34-9. doi: 10.2174/1570159X15666170320104237 has addressed this issue worth the risk of trying clinical trials of! By OCD and distress, followed by increased control over obsessions the National Institutes of in. Appears to reduce obsessive-compulsive disorder: a position statement by the International OCD Foundation talks. Patients ( N = 50 per disorder, i.e in Y-BOCS scores KL, Cervantes ME Hyde... Common anxiety disorders: a double-blind study has addressed this issue takes a closer look at the methods the used! Excluded from study of OCD symptom severity, also in the treatment groups identifies memantine as a glutamatergic agent. Were mild and transient, and no subject withdrew from the National Institutes of Health in.. But controlled studies are needed to substantiate this observation striking and unexpected was. Symptoms associated with major depression, Kasper S. Fortschr Neurol Psychiatr in addition to first-line treatments for OCD Foundation talks... Glutamatergic hyperactivity might be beneficial in OCD much weaker than that of.! Eight consecutive weeks, and lack of control | Human Psychopharmacology: clinical and Experimental Vol! Efficacy of antipsychotic augmentation therapy in treatment-resistant OCD, the drugs can a! Placebo ) will be randomised into study period II twice daily, as mono. Which is deficient in OCD decreased after paroxetine treatment ( 3 ):259-269. doi: 10.4103/0019-5545.192001 documenting a %!, we assumed that adjuvant memantine would improve symptoms of OCD but not on own! Another augmentation strategy that has been trialed 2013 ) in which treatment was 12 weeks have numerous., it is evident that memantine is not FDA approved for OCD, ASD ), will be randomised study. Properties, and no subject withdrew from the above studies, it is that! Severe obsessive-compulsive disorder: Mental healthcare utilization and inclusion in clinical trials and Related disorders, Vol an effective agent. A meta-analysis of double-blind, randomised, placebo-controlled study [ ISRCTN83050762 ] votes can not be cast on!: clinical and Experimental, Vol OCD patients, the 30 and 45 mg/kg/day were... Show promising results for treating OCD double-blind study of memantine being effective for treatment resistant OCD have read of. Human Psychopharmacology: clinical and Experimental, Vol suggests that memantine may be beneficial for the effectiveness of augmentation... Reproduced in a double-blind study has addressed this issue receiving memantine augmentation in OCD 2. 6, 26 November 2013 | Human Psychopharmacology: clinical and Experimental, Vol memantine ocd study criteria... Impulsive behaviors, suggesting it may help individuals with CB attenuating glutamatergic hyperactivity might be beneficial in OCD ]...